| Expression pattern: |
DN |
| Associated gene: |
IGF2BP1, CCL5 mRNA |
| Associated microRNA: |
- |
| Biological function: |
CircMAPK1 suppresses LUAD tumor growth and promotes intratumoral CD8 + T cell infiltration/recruitment. |
| Molecular mechanism: |
CircMAPK1 binds IGF2BP1 in the cytoplasm and induces IGF2BP1 occupancy on the 3′UTR of CCL5 mRNA, thereby maintaining CCL5 mRNA stability and promoting CCL5-mediated CD8 + T cell recruitment. |
| Biological pathway or process: |
immune regulation (promotes); mRNA stability (promotes); proliferation (inhibits) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; RT-qPCR; RNase R Treatment; Actinomycin D / DRB Stability Assay; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; Transfection; Transwell Assay; Flow Cytometry（Non-apoptosis/cycle）; In Vivo Animal Model; IHC (Immunohistochemistry); ELISA; Western Blot; Bioinformatics Analysis |
| Clinical significance: |
CircMAPK1 is positively associated with CD8 + T cell infiltration and is proposed as a potential nucleic acid drug to improve immunotherapy response efficiency combined with ICB. |
| Description: |
CircMAPK1 is down-regulated in LUAD and acts as an anti-tumor microenvironment-associated circRNA. It binds IGF2BP1 in the cytoplasm, promotes IGF2BP1-dependent stabilization of CCL5 mRNA, increases CCL5 expression, and thereby enhances CD8 + T cell recruitment/infiltration. The study suggests circMAPK1 may be a nucleic acid drug candidate to improve ICB immunotherapy response. |
| Confidence score: |
0.8658 |